The U.S. Food & Drug Administration 's ( FDA ) Oncologic Drugs Advisory Committee ( ODAC ) will review the New Drug Application ( NDA ) for pixantrone for the treatment of relapsed / refractory aggressive non-Hodgkin 's lymphoma ( NHL ) on February 10 , 2010 .